2018 - Herzenberg Lectureship Award
Eric Long, PhD
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Dr. Long has a biochemistry degree from the ETH Zürich, Switzerland, and a Ph.D. in molecular biology from the University of Geneva, Switzerland. After postdoctoral research at the Carnegie Institution for Science and the National Cancer Institute, he returned to Geneva as a faculty member in the Department of Microbiology. There, he applied molecular approaches to isolate the first cDNA clones for MHC class II molecules. In 1983, he joined the Laboratory of Immunogenetics at the National Institute of Allergy and Infectious Diseases, NIH. While studying processing pathways for antigen presentation to CD4 T cells, he discovered that MHC-II can present endogenous antigens through a pathway that is independent of the transporter for antigen presentation. He became Senior Investigator and Head of the Molecular and Cellular Immunology Section in 1988. In the mid-90’s, his main interest turned to the regulation and function of natural killer (NK) cells, after his team identified molecular clones for KIR, a family of NK cell inhibitory receptors that prevent killing of healthy cells. In 2001, this work was selected as one of the Basic Discoveries in Biology by the NIH Intramural Research Program. The discovery of the signaling basis for inhibition by these receptors was named one of the “classic papers that present seminal insights into natural killer cell function” by Nature Immunology in 2008, and one of the "Pillars of Immunology" by the Journal of Immunology in 2013. More recently, his research reported on imaging of the dynamics of receptor–ligand interactions at inhibitory immunological synapses, demonstrated activation of NK cells through synergistic combinations of coactivation receptors, and a reprogramming of NK cells to promote vascular remodeling through a specialized receptor for soluble HLA-G. His current work includes studies on the role of NK cells in providing protection against malaria in individuals living in an area of high Plasmodium falciparum transmission.
2018 ORVCA Herzenberg Lecture
Taming and Training Natural Killers
Eric Long (NIAID, National Institutes of Health)
The immune system includes cytotoxic cells, known as Natural Killers, that eliminate virus-infected cells and tumor cells. Unlike cytotoxic T cells, NK cells do not have antigen-specific receptors. Instead, multiple levels of regulation provide tight control of NK cell cytotoxicity. First, there is separation of duties among activation receptors. Adhesion receptors are required for tight contact with target cells and polarization of the cytotoxic machinery toward the target. Other activation receptors must be engaged to release inducers of programmed cell death from polarized cytolytic granules in NK cells. This degranulation is activated through synergistic combinations of pairs of co-activation receptors. Second, NK cells are kept in check by dominant inhibitory receptors, some of which bind MHC class I molecules. Most healthy cells express MHC-I and resist attack by NK
2015 - Herzenberg Lectureship Award
Dr. C. Garrison Fathman, Professor of Medicine and Chief of the Division of Immunology and Rheumatology at Stanford University School of Medicine, also serves as Past Chairman of the Federation of Clinical Immunology Societies (FOCIS) and Director of the Center for Clinical Immunology at Stanford (CCIS).
Dr. Fathman’s contributions in translational medicine in the areas of cellular and molecular immunology, as well as adoptive cellular gene therapy, have brought him international recognition. In particular, he is acclaimed for his establishment and exploitation of the technologies of antigen-specific T-cell cloning and adoptive cellular gene therapy, accomplishments that have facilitated a remarkable series of subsequent advances in understanding conventional immune response and treating autoimmune diseases.
As Founder and Past Chairman of FOCIS, Dr. Fathman led an extremely successful international effort to acknowledge and develop the field of clinical immunology. As Director of the CCIS, the Stanford-based FOCIS Center of Excellence, Dr. Fathman has initiated multi-disciplinary studies to generate novel approaches for the treatment of autoimmune diseases, including insulin-dependent diabetes mellitus, rheumatoid arthritis, and multiple sclerosis. He has also developed state-of-the-art technologies of genomics, proteomics, and metabolomics to integrate approaches to diagnosis, prognosis, and therapy of these diseases.
2014 - Herzenberg Lectureship Award
Lewis Lanier, Ph.D (on the left) obtained his B.S. in Biology from Virginia Tech and Ph.D. in Microbiology and Immunology from the University of North Carolina – Chapel Hill. After postdoctoral studies at the Lineberg Cancer Center at the UNC – Chapel Hill and then as a Damon Runyon – Walter Winchell Cancer Research Fellow at the University of New Mexico, he joined the Research & Development Department at the Becton Dickinson Monoclonal Center in Mountain View, CA. In 1990, he joined the DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California, where he advanced to Director of Immunobiology. In 1999, Dr. Lanier joined the faculty of UCSF School of Medicine in San Francisco. His research group studies Natural Killer (NK) cells, which recognize and eliminate cells that have become transformed or infected by viruses.
2013 - Herzenberg Lectureship Award
Brent Wood, MD, Ph.D (on the right) obtained his MD and PhD from Loma Linda University followed by a residency in Anatomic and Clinical Pathology at the University of Washington in Seattle. After a fellowship in Hematopathology at the University of Washington, Dr. Wood accepted a faculty position in the Department of Laboratory Medicine at the University of Washington where he is currently Professor and Director of the Hematopathology Laboratory. His responsibilities include extensive clinical service work and teaching Hematopathology to medical technology students, medical students, residents and fellows. Flow cytometry is an area of particular interest for Dr. Wood and he is responsible for implementing the first use of 9 and 10 color flow cytometry in the clinical laboratory and exploiting its potential for the identification of minimal residual disease in acute lymphoid and myeloid leukemia. His laboratory serves as one of two national reference laboratories for the identification of minimal residual disease in childhood acute lymphoblastic leukemia for the Children's Oncology Group and is involved in similar protocols with the Southwest Oncology Group. Dr. Wood lectures both nationally and internationally on clinical applications of flow cytometry and is President of the International Clinical Cytometry Society.
Dr. Garry Nolan recieved his undergraduate degree from Cornell Univerisity in Genetics emphasizing his research on Rhizobium Genetics, later under the direction of the Leonard and Leonore Herzenberg lab he recieved his PhD in Genetics from Stanford University on CD8 cloning; heritability of transcription states and FACS-Gal assay for in vivo measure of transcription. Dr. Nolan then completed his Postdoctoral at MIT/Rockefeller University in the Laboratory of David Baltimore focusing his studies on NF-kappa B, Bcl-3, BOSC23 transient retroviral producer systems.
Dr. Nolan now runs his own lab at Stanford University and has become a reknown scientist and expertise in studying cancer, autoimmunity, and the molecular manners in which single cells can be distinguished from normal human tissues, and their biology. His lab uses advanced Flow Cytometry analysis (FACS) of phospho proteins in single cells. They have successfully developed advanced signaling analysis approaches at single cell levels, coupled these to high throughput proteomics technologies and Bayesian mathematics to facilitate understanding of signaling pathways in normal and diseased cells.For more information on his lab and their studies visit the Nolan Lab website to learn more.